Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer

American Journal of Cancer Research

Volumn 5, Issue 6, 2015, Pages 2064-2074

  Teng, Feifei ^a   Mu, Dianbin ^a   Meng, Xiangjiao ^a   Kong, Li ^a   Zhu, Hui ^a   Liu, Sujing ^a   Zhang, Jianbo ^a   Yu, Jinming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Chemoradiotherapy; Inflammation; Lymphocytes; Prognosis; Rectal cancer

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; FLUOROPYRIMIDINE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; RECTUM CANCER; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

EID: 85006198867     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Pahlman L, Glimelius B and van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer:12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-582.
3. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687.
4. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, Mc-Neese MD, Buzdar AU, Hortobagyi GN and Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
5. Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, Zhu K, Dou X, Chen D and Yu J. Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis. Cancer Sci 2014; 105: 818-824.
6. Gooden MJ, de Bock GH, Leffers N, Daemen T and Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
7. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C and Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res 2011; 71: 5601-5605.
8. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M and Malesci A. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009; 10: 877-884.
9. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G and Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014; 25: 611-618.
10. Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, Nason KS, Landreneau RJ, Luketich JD and Schuchert MJ. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res 2011; 171: 1-5.
11. Schumacher K, Haensch W, Roefzaad C and Schlag PM. Prognostic significance of activated CD8 (+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-3936.
12. Wahlin BE, Sander B, Christensson B and Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13: 388-397.
13. Pelletier MP, Edwardes MD, Michel RP, Halwani F and Morin JE. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 2001; 44: 180-188.
14. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964.
15. Order SE. The effects of therapeutic irradiation on lymphocytes and immunity. Cancer 1977; 39: 737-743.
16. Kalbasi A, June CH, Haas N and Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest 2013; 123: 2756-2763.
17. Balermpas P, Rodel F, Weiss C, Rodel C and Fokas E. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology 2014; 3:e27403.
18. Yasuda K, Nirei T, Sunami E, Nagawa H and Kitayama J. Density of CD4 (+) and CD8 (+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol 2011; 6: 49.
19. Dworak O, Keilholz L and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23.
20. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ and Sotiriou C. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98. J Clin Oncol 2013; 31:860-867.
21. Shinto E, Hase K, Hashiguchi Y, Sekizawa A, Ueno H, Shikina A, Kajiwara Y, Kobayashi H, Ishiguro M and Yamamoto J. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann Surg Oncol 2014; 21 Suppl 3: S414-421.
22. Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss EM, Fietkau R and Gaipl US. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 2014; 63: 29-36.
23. Formenti SC and Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105: 256-265.
24. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S and Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
25. Plotnikov A, Niego B, Ophir R, Korenstein R and Keisari Y. Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy. Prostate 2006; 66:1620-1630.
26. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G and Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
27. Gupta A, Sharma A, von Boehmer L, Surace L, Knuth A and van den Broek M. Radiotherapy supports protective tumor-specific immunity. Oncoimmunology 2012; 1: 1610-1611.
28. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C and Loi S. Molecular pathways:involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013; 19: 28-33.
29. Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG and McMillan DC. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer 2014; 50: 309-319.
30. Callahan MK and Wolchok JD. At the bedside:CTLA-4-and PD-1-blocking antibodies in can cer immunotherapy. J Leukoc Biol 2013; 94:41-53.
31. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N and Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189: 487-495.
32. Roxburgh CS and McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012; 38: 451-466.